Table 1.
Pretreatment Demographic and Clinical Features of the Study Sample
| Medication Group | Topiramate (n=56) | Placebo (n=66) | Statistic, P-Value1 |
|---|---|---|---|
|
|
|||
| Demographics | |||
| Sex (male) | 37 (66.1%) | 38 (57.6%) | χ2=0.92, p=0.34 |
| Age2 | 50.7 (7.3) | 53.1 (7.3) | t=1.81, p=0.073 |
| Married or Partnered | 37 (66.1%) | 47 (71.2%) | χ2=0.37, p=0.54 |
| Education2 | 15.6 (2.2) | 15.2 (2.4) | t=−1.15, p=0.25 |
| Clinical Features | |||
| Lifetime Major Depression | 13 (23.2%) | 20 (30.3%) | χ2=0.77, p=0.38 |
| Beck Depression Inventory score2 | 5.9 (4.4) | 6.8 (5.2) | t=0.96, p=0.34 |
| Current Antidepressant Treatment | 10 (17.9%) | 12 (18.2%) | χ2=0.002, p=0.96 |
| 90-day pretreatment drinking | |||
| Proportion of Days Abstinent2 | 0.11 (0.15) | 0.11 (0.14) | t=−0.15, p=0.88 |
| Proportion of Heavy Drinking Days2 | 0.68 (0.27) | 0.66 (0.27) | t=−0.44, p=0.66 |
| Body Mass Index (kg/m2)2 | 29.1 (4.2) | 28.5 (4.6) | t=−0.71, p=0.48 |
1
for χ2 tests, df=1; for t-tests, df=120
2
mean (SD)